10 news items
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
AMGN
GILD
KYMR
20 Jun 24
and tumor response. The ASCO annual meeting will take place from May 31 – June 4, 2024, in Chicago, Illinois. "The two abstracts that we
Cracking The Code: Understanding Analyst Reviews For Kymera Therapeutics
KYMR
17 Jun 24
Outperform
$53.00
-
Key Insights:
Action Taken: In response
Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
KYMR
14 Jun 24
initial clinical proof of concept across multiple hematological malignancies, including complete responses in two patients with Hodgkin's lymphoma
Reported Saturday, Kymera Therapeutics Showcased New Clinical Findings From The Ongoing Phase 1 Study Of Its MDM2 Degrader, KT-253, At The ASCO 2024
KYMR
3 Jun 24
responses in MCC and AML
Evidence of target engagement and potent upregulation of p53 pathway biomarkers even at the lowest dose levels
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
KYMR
1 Jun 24
initial clinical proof of concept in patients with tumor types shown to be sensitive in preclinical models, including responses in MCC and AML
hxlh1 zmj
KYMR
24 May 24
conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related
6qdp 5fzspkizqe551hrhwfd
KYMR
23 May 24
highlights safety, pharmacodynamic and clinical response data with additional data to be presented in a poster session on June 1, 2024
7p9m86z6j4eadmdmc8qh 6e2siz12y
KYMR
14 May 24
Abstract released today highlights safety, pharmacodynamic and clinical response data collected through February 6, 2024 cut-off date
c11elt6svmgwylli6aqm9kkavl9pj9pi9l19h7yj8b
KYMR
14 May 24
highlights safety, pharmacodynamic and clinical response data collected through February 6, 2024 cut-off date
bluzp oebhrscm
KYMR
22 Apr 24
market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments
- Prev
- 1
- Next